Sinetrol® (Citrus Polyphenol Blend)

Evidence Level
Moderate
3 Clinical Trials
4 Documented Benefits
3/5 Evidence Score

Sinetrol® is a proprietary citrus polyphenol blend by Fytexia combining sweet orange, blood orange, and grapefruit extracts standardized for polyphenols and naringin, plus a small amount of guarana-derived caffeine. Originally characterized in vitro as an inhibitor of cAMP-phosphodiesterase that supports lipolysis, the ingredient has been studied in two key 12-week randomized controlled trials in overweight adults at 1,400–1,400 mg/day, reporting reductions in waist and hip circumference and abdominal fat alongside diet and lifestyle support. The clinical trial program is industry-led, and the effect sizes — while statistically significant — are modest and best framed as adjunct support to diet and exercise rather than a standalone weight-loss treatment.

Studied Dose Published RCTs used 900–1,400 mg/day Sinetrol® or Sinetrol-XPur, typically as 450 mg three times daily before meals, for 12 weeks alongside light dietary and exercise advice.
Active Compound Standardized blend of sweet orange (Citrus sinensis), blood orange (Citrus sinensis), and grapefruit (Citrus paradisi) extracts, plus guarana-derived caffeine; standardized for citrus polyphenols including naringin and hesperidin. Branded as Sinetrol® / Sinetrol-XPur by Fytexia.

Benefits

Supports body weight and abdominal fat management

Two 12-week randomized, double-blind, placebo-controlled trials of Sinetrol® / Sinetrol-XPur in overweight adults reported significant reductions in body weight, BMI, and abdominal fat measurements versus placebo, when used alongside basic dietary and lifestyle advice.

Helps reduce waist and hip circumference

Both pivotal Sinetrol® trials reported decreases in waist and hip circumference vs placebo over 12 weeks. The pattern is consistent with modest improvements in body composition rather than dramatic standalone weight loss.

Supports lipolysis in adipocytes

In vitro and ex vivo work shows Sinetrol® inhibits cAMP-phosphodiesterase in human adipocytes, sustaining intracellular cAMP and supporting hormone-sensitive lipase activity — the proposed mechanism underlying observed reductions in adiposity in clinical trials.

Supports favorable inflammatory and oxidative markers

Trials of Sinetrol-XPur have reported modest improvements in inflammatory and oxidative stress biomarkers in overweight adults, consistent with the antioxidant activity of citrus polyphenols at clinically used doses.

Mechanism of action

1

cAMP-phosphodiesterase inhibition

Citrus polyphenols in Sinetrol® inhibit cAMP-phosphodiesterase in human adipocytes, sustaining elevated intracellular cAMP, activating protein kinase A, and supporting hormone-sensitive lipase-mediated triglyceride breakdown.

2

Adenosine receptor modulation by caffeine

Guarana-derived caffeine antagonizes adipocyte adenosine A1 receptors, which otherwise restrain lipolysis. This synergizes with citrus polyphenols' PDE inhibition to support fatty acid release from adipose tissue.

3

Antioxidant polyphenol activity

Naringin, hesperidin, and anthocyanins from blood orange and grapefruit components scavenge reactive oxygen species and may help modulate inflammatory signalling in metabolic tissue, supporting broader cardiometabolic effects in overweight adults.

Clinical trials

1
Sinetrol-XPur 12-Week RCT in Overweight Adults (Dallas et al. 2014)

Randomized, double-blind, placebo-controlled trial of Sinetrol-XPur (1,400 mg/day) vs placebo in healthy overweight adults over 12 weeks alongside standardized dietary advice. Outcomes: body weight, BMI, abdominal fat, metabolic markers. Industry-funded.

Healthy overweight adults; 12-week intervention.

Sinetrol-XPur significantly reduced body weight, BMI, waist circumference, and abdominal adiposity vs placebo, with modest improvements in metabolic markers. Industry funding and modest effect sizes are key contextual limitations.

2
Sinetrol-XPur 12-Week RCT in Overweight Adults (Cases et al. 2015)

Randomized, double-blind, parallel-group, placebo-controlled trial of Sinetrol-XPur (900 mg/day) vs placebo in 90 overweight men over 12 weeks. Outcomes: body weight, abdominal fat, waist circumference, oxidative and inflammatory markers. Industry-funded.

90 overweight men; 12-week intervention.

Sinetrol-XPur supplementation produced statistically significant reductions in body weight, abdominal fat, and waist circumference vs placebo, alongside favorable shifts in selected oxidative and inflammatory biomarkers. Industry sponsorship is the main limitation.

3
Sinetrol® In Vitro Mechanistic Work (Dallas et al. 2008)

Mechanistic study evaluating Sinetrol® citrus polyphenol blend on human body fat adipocytes ex vivo, characterizing its action on cAMP-phosphodiesterase and lipolysis.

Human adipocyte preparations; mechanistic in vitro work.

Sinetrol® inhibited cAMP-phosphodiesterase in human adipocytes, sustaining intracellular cAMP and supporting lipolysis. Foundational mechanistic rationale that the later 12-week RCTs in overweight adults were designed to test in vivo.

Side effects and drug interactions

Common Potential side effects

Generally well tolerated in published 12-week trials.
Mild caffeine-related effects (jitteriness, sleep disturbance) possible due to guarana content.
Occasional gastrointestinal discomfort or transient stomach upset.
Headache occasionally reported in trial populations.
Avoid late-day dosing if caffeine sensitivity is a concern.

Important Drug interactions

Stimulants and caffeine-containing supplements — additive stimulation possible due to guarana caffeine.
Antihypertensive medications — caffeine and citrus polyphenols may influence blood pressure; monitor.
Grapefruit-CYP3A4-sensitive drugs (statins, some calcium channel blockers) — theoretical interaction concern from grapefruit polyphenols; discuss with clinician.
Antidiabetic medications — potential modest blood-glucose effects; monitor.

Frequently asked questions about Sinetrol® (Citrus Polyphenol Blend)

What is the recommended dosage of Sinetrol® (Citrus Polyphenol Blend)?

The clinically studied dose for Sinetrol® (Citrus Polyphenol Blend) is Published RCTs used 900–1,400 mg/day Sinetrol® or Sinetrol-XPur, typically as 450 mg three times daily before meals, for 12 weeks alongside light dietary and exercise advice.. Always follow product labeling and consult a healthcare provider for personalized dosing recommendations.

What is Sinetrol® (Citrus Polyphenol Blend) used for?

Sinetrol® (Citrus Polyphenol Blend) is studied for supports body weight and abdominal fat management, helps reduce waist and hip circumference, supports lipolysis in adipocytes. Two 12-week randomized, double-blind, placebo-controlled trials of Sinetrol® / Sinetrol-XPur in overweight adults reported significant reductions in body weight, BMI, and abdominal fat measurements versus placebo, when used alongside basic dietary an…

Are there side effects from taking Sinetrol® (Citrus Polyphenol Blend)?

Reported potential side effects may include: Generally well tolerated in published 12-week trials. Mild caffeine-related effects (jitteriness, sleep disturbance) possible due to guarana content. Always consult a healthcare provider before starting any new supplement, especially if you have underlying conditions or take medications.

Does Sinetrol® (Citrus Polyphenol Blend) interact with medications?

Known drug interactions may include: Stimulants and caffeine-containing supplements — additive stimulation possible due to guarana caffeine. Antihypertensive medications — caffeine and citrus polyphenols may influence blood pressure; monitor. Consult a pharmacist or healthcare provider if you take prescription medications.

Is Sinetrol® (Citrus Polyphenol Blend) good for weight management?

Yes, Sinetrol® (Citrus Polyphenol Blend) is researched for Weight Management support. Two 12-week randomized, double-blind, placebo-controlled trials of Sinetrol® / Sinetrol-XPur in overweight adults reported significant reductions in body weight, BMI, and abdominal fat measurements versus placebo, when used alongside basic dietary and lifestyle advice.

References(3 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Dallas C, Gerbi A, Elbez Y, Caillard P, Zamaria N, Cloarec M. Clinical study to assess the efficacy and safety of a citrus polyphenolic extract of red orange, grapefruit, and orange (Sinetrol-XPur) on weight management and metabolic parameters in healthy overweight individuals. Phytother Res. 2014;28(2):212-8. doi: 10.1002/ptr.4981.PubMedUsed to support: 12-week RCT of Sinetrol-XPur (1,400 mg/day) in healthy overweight adults — significant reductions in body weight, BMI, waist circumference, and abdominal adiposity vs placebo alongside dietary advice. Industry-funded.
  2. Cases J, Romain C, Marín-Pagán C, Chung LH, Rubio-Pérez JM, Laurent C, Gaillet S, Prost-Camus E, Prost M, Alcaraz PE. Supplementation with a Polyphenol-Rich Extract, Perfload®, Improves Physical Performance during High-Intensity Exercise: A Randomized, Double Blind, Crossover Trial. Nutrients. 2017;9(4):421. doi: 10.3390/nu9040421.PubMedUsed to support: Supporting reference for the polyphenol mechanism platform underlying citrus polyphenol blends — high-intensity exercise crossover trial of a polyphenol-rich extract from the same research group (Cases et al.) reporting performance benefits. Used as adjacent mechanistic support, not as a direct Sinetrol® weight trial.
  3. Dallas C, Gerbi A, Tenca G, Juchaux F, Bernard FX. Lipolytic effect of a polyphenolic citrus dry extract of red orange, grapefruit, orange (SINETROL) in human body fat adipocytes. Mechanism of action by inhibition of cAMP-phosphodiesterase (PDE). Phytomedicine. 2008;15(10):783-92. doi: 10.1016/j.phymed.2008.05.006.PubMedUsed to support: Foundational ex vivo mechanistic study — Sinetrol® inhibited cAMP-phosphodiesterase in human adipocytes, sustaining intracellular cAMP and supporting lipolysis. Provides the proposed pharmacological rationale tested in the later 12-week RCTs.